

## PRODUCT INFORMATION

<b>Common Name</b>	BFCR-4350-A, BFCR-4350A, RG-6160, RO-7187797
<b>Synonyms</b>	BXMAS1;CD307;CD307e;FCRH5;IRTA2;PRO820
<b>Conjugate</b>	PE-conjugated
<b>Applications</b>	Flow Cyt
<b>Endotoxin</b>	Less than 1.0 EU/μg by the LAL method. For <1 EU/mg requirements, please contact us for customization.
<b>Delivery</b>	In Stock
<b>Host Species</b>	Humanized
<b>IgG type</b>	Human IgG1 - kappa
<b>Reactivity</b>	Human
<b>Target</b>	FCRL5
<b>Uniprot ID</b>	Q96RD9
<b>Recommended Dilutions</b>	Flow Cyt 1:200
<b>Description</b>	PE-conjugated Anti-FCRL5(cevostamab biosimilar without anti-CD3 portion) mAb
<b>Storage&amp;Shipping</b>	Store at 2°C-8°C for 6 months
<b>Formulation &amp; Reconstitution</b>	Liquid,PBS with 0.1% Proclin300, 0.18% BSA
<b>Background</b>	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
<b>Usage</b>	Research use only






Figure 1. Flow cytometry analysis with 100  $\mu$ l/test (1:200) PE-conjugated Anti-FCRL5(cevostamab biosimilar without anti-CD3 portion) mAb (BME100089P) on HEK293 cells transfected with human FCRL5 (Blue histogram) or HEK293 cells (Red histogram).

